CClinicalTrials.gg
WithdrawnNCT00786175Updated Aug 24, 2015

A Survey to Evaluate the Rate of Abnormal Glucose Tolerance Among Hong Kong Chinese Subjects With Coronary Heart Disease

An observational study in Coronary Heart Disease and Diabetes Mellitus, sponsored by Chinese University of Hong Kong. Withdrawn at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-24.

Sponsored by Chinese University of Hong Kong · Observational

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

Hypothesis: there is a high prevalence rate of diabetes, including asymptomatic undiagnosed glucose intolerance, among subjects with coronary heart disease in Hong Kong.

A cross-sectional survey is planned to study the rate of undiagnosed diabetes and glucose intolerance among the Chinese patients with coronary heart disease in Hong Kong. The survey results will be important for us to plan the logistics to investigate and manage the potential glucose abnormality of our heart disease patient.

Read the detailed description

Diabetes is becoming an epidemic in Hong Kong, affecting over 10% of population and causing a major burden to the health care system. Over 30-40% of patients admitted to the medical wards of the Hospital Authority hospitals have diabetes as a contributory factor. It was estimated that thirty to fifty percent of patients with stroke, heart failure or acute myocardial infarction have diabetes as a key causative factor. However, the exact prevalence rate of diabetes, including asymptomatic undiagnosed glucose intolerance, among subjects with coronary heart disease is still unknown in Hong Kong. Many heart disease patients with undiagnosed diabetes remained being untreated on their abnormal glycemic status, which will further aggravate the heart disease and impair the prognosis.

The investigators plan to conduct a cross-sectional survey to study the rate of undiagnosed diabetes and glucose intolerance among the Chinese patients with coronary heart disease in Hong Kong. The survey results will be important for us to plan the logistics to investigate and manage the potential glucose abnormality of our heart disease patient.

02

Conditions studied

03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

Browse Heart Diseases studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hong Kong Chinese with history of coronary heart disease being diagnosed in 2008 in HA hospitals

Inclusion criteria

  1. Patients aged 18 years
  2. Subjects admitted to Hospital Authority hospital as in-patients (AHNH) with the diagnosis of coronary heart disease (ICD code 410-414) during the period 1 April 2007 to 31 March 2008.
  3. Subjects admitted to AHNH for the procedure Percutaneous Coronary Intervention (PCI) to manage coronary heart disease.

Exclusion criteria

Exclusion Criteria:

  1. Known Type 1 diabetes defined as history of ketosis [acute symptoms with heavy ketonuria (>3+) or ketoacidosis] or heavy ketonuria (3+) or continuous requirement of insulin treatment within one year of diagnosis and thereafter.
  2. Patients with terminal malignancy or other life-threatening diseases with less than 6-month expected survival
  3. Patients with a mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
0 participants (actual)
06

Study locations

1 site
  • Hong Kong Institute of Diabetes and Obesity
    Hong Kong, China
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00786175
Lead sponsor
Chinese University of Hong Kong
Responsible party
Juliana Chan (Chair Professor of Medicine and Therapeutics, Chinese University of Hong Kong) — Principal investigator
First posted
Nov 6, 2008
Start date
Oct 2008
Primary completion
Dec 2018 (estimated)
Completion
Dec 2018 (estimated)
Last update
Aug 24, 2015

Study contacts

Gary Ko, MD
principal investigator · Asia Diabetes Foundation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion